CYP2C9 - cytochrome P450 family 2 subfamily C member 9 Gene
Also Known as CPC9; CYP2C; CYP2C10; CYPIIC9; P450-2C9; P450IIC9
Species: Homo sapiens
About CYP2C9
This gene has 5 transcripts (splice variants), 43 orthologues, 15 paralogues and is associated with 1 phenotype. Biased expression in liver (RPKM 331.8), duodenum (RPKM 60.3) and 1 other tissue.
Summary
This gene encodes a member of the Cytochrome P450 superfamily of Enzymes. The Cytochrome P450 proteins are monooxygenases which catalyze many reactions involved in drug metabolism and synthesis of Cholesterol, Steroids and Other lipids. This protein localizes to the endoplasmic reticulum and its expression is induced by rifampin. The enzyme is known to metabolize many xenobiotics, including phenytoin, tolbutamide, ibuprofen and S-warfarin. Studies identifying individuals who are poor metabolizers of phenytoin and tolbutamide suggest that this gene is polymorphic. The gene is located within a cluster of Cytochrome P450 genes on chromosome 10q24. [provided by RefSeq, Jul 2008]
CYP2C9 Products (1)
| mRNA | Protein | Name |
|---|---|---|
| NM_000771.4 | NP_000762.2 | cytochrome P450 2C9 precursor |
| Molecular Function GO Annotation | Evidence | References | Source |
|---|---|---|---|
| enables arachidonate epoxygenase activity |
IDA
IDA: Inferred from direct assay
|
7574697 | GOA |
| enables caffeine oxidase activity |
IDA
IDA: Inferred from direct assay
|
18619574 | GOA |
| enables monooxygenase activity |
IDA
IDA: Inferred from direct assay
|
15766564 | GOA |
| enables oxidoreductase activity |
IDA
IDA: Inferred from direct assay
|
16401082 | GOA |
| enables steroid hydroxylase activity |
IMP
IMP: Inferred from mutant phenotype
|
18356043 | GOA |
| Cellular Component GO Annotation | Evidence | References | Source |
|---|---|---|---|
| located in intracellular membrane-bounded organelle |
IDA
IDA: Inferred from direct assay
|
9618440 | GOA |
CYP2C9 Protein Structure
p450: Cytochrome P450 (30 - 487)
- 0
- 100
- 200
- 300
- 400
- 490 a.a.
| Protein Preferred Names | Protein Names | |
|---|---|---|
|
cytochrome P450 2C9 |
|
CYP2C9 Antibodies
| Cat. No. | Product Name | Application | Reactivity |
|---|---|---|---|
| HY-P82421 | Cytochrome P450 2C9 Antibody (YA2166) | WB, ICC/IF, FC | Human |
Related Diseases
| Diseases | Alias | |
|---|---|---|
| Coumarin Resistance |
|
|
| Multiple Chemical Sensitivity |
|
|
| Budd-Chiari Syndrome |
|
|
| Halothane Hepatitis |
|
|
| Sulfamethoxazole Allergy |
|
|
| Vitamin K-Dependent Clotting Factors, Combined Deficiency Of, 2 |
|
|
| Impotence |
|
|
| Severe Cutaneous Adverse Reaction |
|
|
| Angiodysplasia Of Intestine |
|
|
| Drug-Induced Hepatitis |
|
|
| Arthritis |
|
|
| Marfan Syndrome |
|
|
| Trimethoprim Allergy |
|
|
| Pulmonary Hypertension |
|
|
| Hypertrophy Of Tongue Papillae |
|
|
| Myocardial Infarction |
|
|
| Invasive Aspergillosis |
|
|
| Ceftazidime Allergy |
|
|
| Abacavir Allergy |
|
|
| Sudden Infant Death Syndrome |
|
|
| Phenytoin Allergy |
|
|
| Epilepsy |
|
|
| Colorectal Cancer |
|
|
| Heart Conduction Disease |
|
|
| Lennox-Gastaut Syndrome |
|
|
| Gilbert Syndrome |
|
|
| Hypertension, Essential |
|
|
| Diabetes Mellitus |
|
|
| Bilirubin Metabolic Disorder |
|
|
| Breast Cancer |
|
|